Concepedia

Muralidhar Beeram

MB

59

Publications

6.3K

Citations

33

H-Index

2003

Active since

Affiliations

South Texas Accelerated Research Therapeutics(Current)

Sarah Cannon

Eli Lilly (United States)

Dana-Farber Cancer Institute

The University of Texas Health Science Center at San Antonio

Muralidhar Beeram is an author at South Texas Accelerated Research Therapeutics specializing in oncology, medicine, and cancer therapeutics.

Top concepts

Publications per year

2003–2025

59

Publications

59

Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors

Amita Patnaik, Soonmo Peter Kang, Drew Rasco et al. · Clinical Cancer Research · 2015 · 767 citations

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik, Lee S. Rosen, Sara M. Tolaney et al. · Cancer Discovery · 2016 · 740 citations · Full text

Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer

Ian E. Krop, Muralidhar Beeram, Shanu Modi et al. · Journal of Clinical Oncology · 2010 · 590 citations

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik et al. · Journal of Clinical Oncology · 2019 · 564 citations · Full text

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer

Toshio Shimizu, Anthony W. Tolcher, Kyriakos P. Papadopoulos et al. · Clinical Cancer Research · 2012 · 429 citations

Rows per page

1–5 of 59